Bruised and battered by its failings with the controversial Alzheimer’s drug Aduhelm, Biogen is looking to right the ship with a new helmsman. The company is on the hunt for a new chief executive officer. 

Medicare wants to start paying hospitals fixed amounts for hip and knee replacements, rather than letting providers bill individually for each surgical and recovery service provided to older Americans, health […]